J&J's Marketing Of Risperdal For Children Slammed In Trial

By Matt Fair (October 15, 2015, 6:32 PM EDT) -- Trial in a third case over abnormal breast growth allegedly caused by a Johnson & Johnson unit's antipsychotic drug got underway on Thursday as a Philadelphia jury heard arguments that the pharmaceutical giant had worked to peddle the medication to pediatric doctors despite a lack of approval from federal regulators.

Kline & Specter PC attorney Tom Kline told the jury that improper marketing by Janssen Pharmaceuticals Inc. had led a pediatric neurologist to prescribe Risperdal to an 11-year-old boy to treat symptoms of Tourette dyndrome without a proper understanding of the risks of breast growth associated with the drug.

"Risperdal [is]...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Read the full article

Already a subscriber? Click here to login